FDA Approved: KISQALI FEMARA CO-PACK — Supplemental Application (Novartis Pharmaceuticals Corporation)

View source ↗

Summary

FDA approved a supplemental application to offer a Kisqali (ribociclib) and Femara (letrozole) co-pack, enabling combination therapy in breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• FEMARA (letrozole)
• KISQALI (ribociclib)

Snippet

SUPPL AP for KISQALI FEMARA CO-PACK (LETROZOLE AND RIBOCICLIB)